The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Balversa (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC). Specifically, the indication covers patients harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received at least one line of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!